Date: Aug 26, 2022

Your Name: Maria A. Gonzalez-Carmona

Manuscript Title: Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a

single center experience and review of literature

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

	Name all entitles with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	GO 1874/1-2 grant from "Deutsche Forschungsgemeinschaft" (DFG) BONFOR from the University of Bonn grant number 109255 from "Deutsche Krebshilfe" (German Cancer Aid) the Reuthersche endowment fund of the University of Bonn	

2 Grants or contracts from any entity (if not indicated in item #1 above). 3 Royalties or licenses			Time frame: past 36 months
4 Consulting fees	2	any entity (if not indicated	er anna mar ann an ann an ann an ann ann an an an a
S Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events X None	3	Royalties or licenses	X None
Jectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel. 8 Patents planned, Issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- 15 Mone 16 Payment for expert X None X None A None	4	Consulting fees	_X_None
speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Moniforing Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock optionsX_None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or nonX_None	5		X_None
8 Patents planned, Issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- X None X None A None		speakers bureaus, manuscript writing or	
8 Patents planned, issued or pending 9 Participation on a Data X None Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non X None	6	Payment for expert	X None
pending Participation on a Data Safety Monitoring Board or Advisory Board Deadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options X None X None Receipt of equipment, materials, drugs, medical writing, gifts or other services X None X None X None X None	7		X. None
pending Participation on a Data Safety Monitoring Board or Advisory Board Deadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options X None X None Receipt of equipment, materials, drugs, medical writing, gifts or other services X None X None X None X None			
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- X None	8		XNone
Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options X_None Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- X_None Roche, Eisai, BMS, MSD advisory boards A Z None X_None X_None	9	Safety Monitoring Board or	X_None
12 Receipt of equipment,X_None	10	in other board, society, committee or advocacy	
12 Receipt of equipment, X_None	11	Stock or stock options	
	12	materials, drugs, medical writing, gifts or other	XNone
financial interests	13	Other financial or non- financial interests	X None

This work was supported by the following grants awarded to MG: GO 1874/1-2 grant from "Deutsche Forschungsgemeinschaft" (DFG), BONFOR from the University of Bonn, grant number 109255 from "Deutsche Krebshilfe" (German Cancer Aid) and a grant from the Reuthersche endowment fund of the University of Bonn. MG has contributed to advisory boards for Roche, Eisai, BMS, MSD and AZ. However, these activities have no potential conflicts of interest with the manuscript.

Please place an "X" next to the following statement to indicate your agreement:

_X_I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Maria A. fortale 18-007-2022

manuscript number: J60-22-632-CL

ICMJE DISCLOSURE FORM

Date: 26.	Acis. 26th. 2022
Your Name:	Pone De chartien stressburg
Manuscript Title:	accord line and third line the capy with
Manuscript numl	ber (if known):
Cancer; o	single center experience and review of literature

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
No.	tillians i skyrter trakt i resolvade	Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
1	SOUTH TO SEE SEE SEES SEE	Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		AND PRINCE OF BUILDING AND A
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony	//	
7	Support for attending	None	
	meetings and/or travel		
	NAME OF THE PERSON OF THE PERS		
	SECTION AND ADDRESS OF THE PARTY OF THE PART		
	The state of the latest the state of the sta		
8	Patents planned, issued or	None	
	pending	* * *	
^	Dark in the case of the case o	A Nove	
9	Participation on a Data Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	√ None	
10	in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
		/	
		性的 自由 人名英格兰人姓氏	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services	,,	
13	Other financial or non-	None	
	financial interests		张兴兴,但是"张兴兴"的"张兴兴"。

None.			

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

	lug. 26 th . 20 :: Prof. Dr. J					
Tour Ivallie	PIUL DI. J	OIE Kalli				
Manuscrip	t Title:	Second-line	and third-line	therapy with	nanoliposomal	irinotecan
(nal-IRI) in panc	reatic cancer:	a single cente	er experience	and review of	
literatu	re					
		known): _JGO-2	2-632-CL			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	X_None
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	X_None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None
13	Other financial or non- financial interests	XNone

None.	 	·		

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: August 9 th , 2022	
Your Name: Tim R. Glowka	
Manuscript Title: Second-line and third-line therapy with nanoliposomal irinotecan	
(nal-IRI) in pancreatic cancer: a single center experience and review of literature	
Manuscript number (if known): _JGO-22-632-CL	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	-

		(13m) 1 i 1 i i i i	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
		New American	
8	Patents planned, issued or	XNone	
	pending	The all prompts the total	Althought at a wall one to real content. It was into the
			The second
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role in other board, society,	Board member of the German Pancreas Club	Unpaid
	committee or advocacy	A STATE OF THE PARTY OF THE PAR	II shakes significant power of the test significant
	group, paid or unpaid		Control partition of the control of the second
11	Stock or stock options	X None	
12	Receipt of equipment,	X_None	e pully see adversarious and a second and
	materials, drugs, medical		
	writing, gifts or other services	E ANTASAREAE	
13	Other financial or non-	X None	
	financial interests		

No conflict of interest. No connection to the submitted manuscript.

The German Pancreas Club (www.pankreasclub.de) is the society of German pancreatologists founded in 1980. Tim Glowka was elected congress president for 2024 on the annual conference in 2022.

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Priv.-Doz. Dr. med. Tim R. Glowka stv. Geschäftsführender Oberarzt Klinik und Poliklinik

für Allgemein-, Viszeral-, Thorax- und Gefäßchirurgie

Universitäts linikum Bonn Venusberg-Campus

Tel. 0228 287-15128 Fax: 0228 287-14856

Date: Aug. 26 th , 2022	
Your Name: Prof. Dr. Peter Brossart	_
Manuscript Title:Second-line and third-line therapy with nanoliposomal	irinotecan
(nal-IRI) in pancreatic cancer: a single center experience and review of	
literature	
Manuscript number (if known):JGO-22-632-CL	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	ASSESSMENT AND
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	_X_None	

None.	4		

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

	A acth	2022				
Jate: _	Aug. 26th, 2	2022				
our Na	ame: Dr. <u>Geo</u> i	rg Feldmann				
Manus	ript Title:	Second-line	and third-line	therapy with	nanoliposomal	irinotecan
(nal-1	RI) in par	ncreatic cancer:	a single cente	r experience	and review of	
litera	ture					
Manus	ript number	(if known): _JGO-2	2-632-CL			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

Payment or honoraria for	XNone	200 Sec. of Se
speakers bureaus, manuscript writing or educational events		- To hely may would be placed to be southly in the second of the second
Payment for expert testimony	XNone	
Support for attending meetings and/or travel	XNone	COLUMN OF BUYERS AND
4 to alternating	tion's Machinism pay's .	nach protestieth yll ag en ega fan it macht ûne yn ernoge
Patents planned, issued or pending	XNone	
Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
Stock or stock options	XNone	
Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
Other financial or non- financial interests	XNone	
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert

None.		

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

m. Teldreun 78.8.7072

Date:	Aug. 26 th ,	2022				
Your N	lame: <u>Milka N</u>	// Arinova				_
Manus	script Title:	Second-line	and third-line	therapy with	nanoliposomal	irinotecan
(nal-	IRI) in pa	ncreatic cancer:	a single cente	er experience	and review of	
liter	ature					
Manus	script numbei	(if known): _JGO-2	2-632-CL			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone
6	Payment for expert testimony	XNone
7	Support for attending meetings and/or travel	XNone
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	XNone
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None
13	Other financial or non- financial interests	XNone

None.	
-------	--

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Bonn, 26.08.2021

Milka Mannova

ICMJE DISCLOSURE FORM
Date: 26.08.2022
Your Name: Or. Robert Mahn
Manuscript Title: 760-22 62-CL 1 gerand line and
Manuscript Title: JGO-22-632-Cl-, second line and Manuscript number (if known): Third line the sapy with nanoliposemal innotecan in Cancreatic Cancer experience and review
innotecan in Concreatic Concer experience and review
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are of related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.
The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.
The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

_			
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	The state of the s	
6	Payment for expert	None	
•	testimony	None	
	Costiniony	\\	
		1	
7	Support for attending	None	
	meetings and/or travel		
3,	THE PROPERTY OF THE PARTY OF TH	the field party of the second	THE ROLL OF STREET AND THE PROPERTY OF THE PARTY OF THE P
	计划是对外的工程的		TO THE REAL PROPERTY AND ADDRESS OF THE PARTY OF THE PART
	A STATE OF THE PARTY.	Company of the Compan	HER WORLD VINGER AS THE ARM HER PROPERTY.
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	A ST THE THE PARTY OF THE PARTY
	Safety Monitoring Board or	<u> </u>	
	Advisory Board		
10	Leadership or fiduciary role	2 Name	
10		None	
	in other board, society,	/\	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
14	materials, drugs, medical	None	
	writing, gifts or other		
	services	,	
13	Other financial or non-	None	
	financial interests	N	

None.	

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

7. John 5-3-22

Date:	Aug. 26th, 202	22				
Your N	lame: Dr. <u>Taotao</u>	Zhou				
Manus	cript Title:	Second-line	and third-line	therapy with	nanoliposomal	irinotecan
(nal-	IRI) in panc:	reatic cancer:	a single cente	r experience	and review of	
liter	ature		-			
Manus	cript number (if	known): _JGO-2	2-632-CL			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	E BERTAN ÎN DE NOVÎ PÎLÎ PARÇÎ JE PÎNÎ ÎN ÎN ÎNÎ ÎN ÎN ÎN ÎN ÎN ÎN ÎN ÎN ÎN
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	

None.		

Please place an "X" next to the following statement to indicate your agreement:

ate: _	Aug. 26th, 202	2			
our N	ame: Dr. <u>Farsan</u> e	h Sadeghlar			
(nal-I	IRI) in pancı		and third-line a single cente		irinotecan
Vianus	cript number (if	known): _JGO-2	22-632-CL		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X_None	
4	Consulting fees	XNone	

ayment or honoraria for ectures, presentations, peakers bureaus, nanuscript writing or ducational events ayment for expert	XNone	
estimony	XNone	
upport for attending neetings and/or travel	XNone	
atents planned, issued or ending	XNone	
articipation on a Data afety Monitoring Board or dvisory Board	XNone	
eadership or fiduciary role n other board, society, ommittee or advocacy roup, paid or unpaid	XNone	
tock or stock options	XNone	
eceipt of equipment, naterials, drugs, medical vriting, gifts or other ervices	X_None	
ther financial or non- nancial interests	XNone	
n a a a a a a a a a a a a a a a a a a a	atents planned, issued or ending articipation on a Data afety Monitoring Board or dvisory Board adership or fiduciary role other board, society, ommittee or advocacy oup, paid or unpaid ock or stock options accept of equipment, aterials, drugs, medical riting, gifts or other ervices	atents planned, issued or ending articipation on a Data afety Monitoring Board or dvisory Board addership or fiduciary role other board, society, pamittee or advocacy roup, paid or unpaid ock or stock options acceipt of equipment, aterials, drugs, medical riting, gifts or other ervices ther financial or non-

Please place an "X" next to the following statement to indicate your agreement:

X_ I certify that I have an	swered every question and have not altered the wording of any of the questions on this
form.	
	Execult Englished
	March Chelque
	1000

Your Name: Alexandra Bartels	
Manuscript Title:Second-line and third-line therapy wit (nal-IRI) in pancreatic cancer: a single center experience	
literature	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
LE		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
ntva :		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	_X_None	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	_X_None	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	X_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	*
11	Stock or stock options	X_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	_X_None	

None.	

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Aexaudia Bafels

Date:	Aug. 26 th , 2022
Your N	Name: Freddy José Frontado Graffe ¹
Manus	script Title:Second-line and third-line therapy with nanoliposomal irinotecan
(nal-	-IRI) in pancreatic cancer: a single center experience and review of
liter	cature
Manus	script number (if known): JGO-22-632-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	_		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNOTIC	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

None.		

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Freddy J. Frontado Graff

Date:	Aug.	2. 26 th , 2022	
Your N	Name:	Christian Möhring	
	Man	nuscript Title: Second-line and third-line therapy with nanoliposomal irinotecan	
	(nal-l	IRI) in pancreatic cancer: a single center experience and review of literature	
Manus	script nu	umber (if known): JGO-22-632-CL	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	X None	
U	testimony		
	,		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
44		V N	
11	Stock or stock options	XNone	
12	Receipt of equipment,	X None	
12	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None.			

Please place an "X" next to the following statement to indicate your agreement:

__X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

C. Möhring